APR 24, 2018 10:43 PM PDT

Methods Used in Drug Discovery and Development

WRITTEN BY: Nouran Amin

The method of choice in drug-discovery in the past two decades has been target-based screening. Now, phenotypic screening is beginning to emerge as a preferable method.


Phenotypic screening involves the screening of a set of candidate molecules being tested based on its ability to exert effects. For example, testing a molecule in cells, isolated from tissues or organs, or animals, to test if molecule exerts side-effects. Historically, phenotypic screening held positive attributes in the identification of the first-in-class drugs, while target-based screening has yielded more best-in-class drugs which was due to the lack of bias when discovering a drug’s mechanism of action. But, phenotypic assays are more of an advantage with respect to the identification of cell active compounds, says Professor Elizabeth Sharlow from the University of Virginia School of Medicine, Virginia, USA.

“Phenotypic assays are challenging because of the need for, often, complicated downstream target deconvolution methodologies,” explains Professor Elizabeth Sharlow from the University of Virginia School of Medicine, “And they are also, in some instances, more time consuming to implement which in the long term may impact throughput. All of this needs to be factored into the overall screening paradigm and cost of the screening strategy.”

The genomic revolution in the last few decades has caused pharmaceutical companies and universities to adopt the ‘target-first’ approach. In other words, their method of reference in the drug discovery process was where a molecule known to be crucial in a disease process is used for screening vast compound libraries in the search for a ‘match’ a.k.a the candidate drug. One advantage to this method, is that many millions of drug-like molecules can be screened, knowing that if you get a match, you already have a potential drug. “Target-based assays, in general, are less time consuming to implement but sometimes are challenged by standard readouts such as enzymatic activity,” says out Professor Sharlow, “Then there’s more sophisticated target-based assays such as those based on protein-protein interactions, which, while more physiologically interesting, are much more complicated to implement.”

 



Overall, both screening strategies are important and necessary for chemical probe and the drug development process. However, there is still a slight rise in phenotypic screening. “Doing drug discovery screens within the cellular context already answers a few of the questions that bedevil the drug discovery process later on, such as ‘how do I make this more soluble?’, or ‘how do I get this into cells?’” explains Dr Mike Howell, Head of Screening at the Francis Crick Institute.

“If you’re a medicinal chemist, you’re probably correctly of the opinion that you can use your magic to make things that are not very soluble or are not very good at getting into cells, better at getting into cells. But there’s a feeling that if you start off with a good cell-based assay then you’ve leapt some of those hurdles inherently by design.”

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 15, 2020
Immunology
APR 15, 2020
Why More Men than Women Die from COVID-19
As of April 9th, over 60% of deaths from COVID-19 in New York state were men. Meanwhile, as of April 6, 82% of patients ...
APR 21, 2020
Immunology
APR 21, 2020
Sino Biological Focuses on Serological Studies of COVID-19
April 17, 2020, Sino Biological announced this week that the company launched the world’s first coronavirus antige ...
APR 20, 2020
Genetics & Genomics
APR 20, 2020
Advances in Gene Therapy for Neurons
New research may aid in the development of gene therapies for diseases like Alzheimer's and Parkinson's.
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
MAY 06, 2020
Drug Discovery & Development
MAY 06, 2020
Why Doctors are Repurposing Drugs to Treat COVID-19
Creating a drug from scratch is a lengthy process. Often taking years, given the rate of infection and deadliness of COV ...
JUN 01, 2020
Neuroscience
JUN 01, 2020
What Causes 'Good' and 'Bad' Trips in the Brain
People who use psychedelics like magic mushrooms, LSD and DMT often describe a feeling of going 'beyond their human ...
Loading Comments...